Literature DB >> 19042034

Delivery of Interferon-gamma by an adenovirus vector blocks herpes simplex virus Type 1 reactivation in vitro and in vivo independent of RNase L and double-stranded RNA-dependent protein kinase pathways.

Daniel J J Carr1, Bobbie A Austin, William P Halford, Patrick M Stuart.   

Abstract

HSV-1 is a significant human pathogen that can result in the loss of sight as a result of episodic reactivation of latent virus from sensory ganglion neurons. In this study the potential efficacy of anti-viral cytokine expression in preventing latent virus reactivation was investigated. Both type I (IFN-beta) and type II (IFN-gamma) IFN transgene expression following transduction of trigeminal ganglion explant cultures significantly reduced the incident of HSV-1 reactivation that in the case of IFN-beta was dependent on the presence of double stranded RNA-dependent protein kinase and RNase L. In vivo, expression of the IFN-gamma but not IFN-beta transgene significantly delayed and reduced the frequency of reactivation of latent mice exposed to UV light without discernable inflammation. This result is the first report that demonstrates the ability to block reactivation using an ectopic cytokine expression system and warrants further exploration as a means to prevent HSV-1 reactivation.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19042034      PMCID: PMC2626643          DOI: 10.1016/j.jneuroim.2008.10.008

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  39 in total

Review 1.  Viral subversion of the immune system.

Authors:  D Tortorella; B E Gewurz; M H Furman; D J Schust; H L Ploegh
Journal:  Annu Rev Immunol       Date:  2000       Impact factor: 28.527

2.  Herpes simplex virus ICP0 and ICP34.5 counteract distinct interferon-induced barriers to virus replication.

Authors:  Karen L Mossman; James R Smiley
Journal:  J Virol       Date:  2002-02       Impact factor: 5.103

Review 3.  Interferons alpha and beta as immune regulators--a new look.

Authors:  C A Biron
Journal:  Immunity       Date:  2001-06       Impact factor: 31.745

4.  Therapeutic immunization with a virion host shutoff-defective, replication-incompetent herpes simplex virus type 1 strain limits recurrent herpetic ocular infection.

Authors:  Tammie L Keadle; Lynda A Morrison; Jessica L Morris; Jay S Pepose; Patrick M Stuart
Journal:  J Virol       Date:  2002-04       Impact factor: 5.103

Review 5.  Herpes simplex virus epidemiology and ocular importance.

Authors:  T J Liesegang
Journal:  Cornea       Date:  2001-01       Impact factor: 2.651

6.  Spontaneous molecular reactivation of herpes simplex virus type 1 latency in mice.

Authors:  Lawrence T Feldman; Aaron R Ellison; Cynthia C Voytek; Li Yang; Philip Krause; Todd P Margolis
Journal:  Proc Natl Acad Sci U S A       Date:  2002-01-02       Impact factor: 11.205

7.  Herpes simplex virus-specific memory CD8+ T cells are selectively activated and retained in latently infected sensory ganglia.

Authors:  Kamal M Khanna; Robert H Bonneau; Paul R Kinchington; Robert L Hendricks
Journal:  Immunity       Date:  2003-05       Impact factor: 31.745

8.  Protection against recurrent ocular herpes simplex virus type 1 disease after therapeutic vaccination of latently infected mice.

Authors:  C M Richards; R Case; T R Hirst; T J Hill; N A Williams
Journal:  J Virol       Date:  2003-06       Impact factor: 5.103

9.  Differential effect of murine alpha/beta interferon transgenes on antagonization of herpes simplex virus type 1 replication.

Authors:  Peter Härle; Vanessa Cull; Martin-Paul Agbaga; Robert Silverman; Bryan R G Williams; Cassandra James; Daniel J J Carr
Journal:  J Virol       Date:  2002-07       Impact factor: 5.103

10.  CD8(+) T cells can block herpes simplex virus type 1 (HSV-1) reactivation from latency in sensory neurons.

Authors:  T Liu; K M Khanna; X Chen; D J Fink; R L Hendricks
Journal:  J Exp Med       Date:  2000-05-01       Impact factor: 14.307

View more
  8 in total

1.  IL-29/IL-28A suppress HSV-1 infection of human NT2-N neurons.

Authors:  Lin Zhou; Jieliang Li; Xu Wang; Li Ye; Wei Hou; Jie Ho; He Li; Wenzhe Ho
Journal:  J Neurovirol       Date:  2011-04-16       Impact factor: 2.643

2.  Immune Escape via a Transient Gene Expression Program Enables Productive Replication of a Latent Pathogen.

Authors:  Jessica A Linderman; Mariko Kobayashi; Vinayak Rayannavar; John J Fak; Robert B Darnell; Moses V Chao; Angus C Wilson; Ian Mohr
Journal:  Cell Rep       Date:  2017-01-31       Impact factor: 9.423

3.  Recurrent herpetic stromal keratitis in mice, a model for studying human HSK.

Authors:  Jessica Morris; Patrick M Stuart; Megan Rogge; Chloe Potter; Nipun Gupta; Xiao-Tang Yin
Journal:  J Vis Exp       Date:  2012-12-18       Impact factor: 1.355

Review 4.  Defining nervous system susceptibility during acute and latent herpes simplex virus-1 infection.

Authors:  Chandra M Menendez; Daniel J J Carr
Journal:  J Neuroimmunol       Date:  2017-03-08       Impact factor: 3.478

5.  VEGF-A expression by HSV-1-infected cells drives corneal lymphangiogenesis.

Authors:  Todd R Wuest; Daniel J J Carr
Journal:  J Exp Med       Date:  2009-12-21       Impact factor: 14.307

6.  Immune characteristics correlating with HSV-1 immune control and effect of squaric acid dibutyl ester on immune characteristics of subjects with frequent herpes labialis episodes.

Authors:  Hugh McTavish; Katherine W Zerebiec; Jay C Zeller; Laurie L Shekels; Mark A Matson; Betsy T Kren
Journal:  Immun Inflamm Dis       Date:  2019-02-12

7.  Case Report: Rapid Recognition and Immune Modulation of Secondary HLH Due to Disseminated HSV Infection.

Authors:  Daniel J McKeone; Theodore K M DeMartini; Robert P Kavanagh; E Scott Halstead
Journal:  Front Pediatr       Date:  2021-07-02       Impact factor: 3.418

Review 8.  Immunological control of herpes simplex virus infections.

Authors:  Kevin P Egan; Sharon Wu; Brian Wigdahl; Stephen R Jennings
Journal:  J Neurovirol       Date:  2013-08-14       Impact factor: 2.643

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.